Physiologically ‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B

In conclusion, the simeprevir PBPK model developed in this study can quantitatively describe the increase in exposures of concomitant drugs and an endogenous biomarker via inhibition of CYP3A4 and OATP1B.

Source: CPT: Pharmacometrics and Systems Pharmacology - September 6, 2023 Category: Drugs & Pharmacology Authors: Shinji Nakayama, Kota Toshimoto, Shinji Yamazaki, Jan Snoeys, Yuichi Sugiyama Tags: ARTICLE Source Type: research